Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (Nasdaq: ATRA) on April 30, 2020, reporting events occurring on April 29, 2020. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Mr. Ron Renaud to the Board of Directors. Effective April 29, 2020, Mr. Renaud was appointed to fill a vacant Board seat and to serve as the Chair of the Board. His initial term expires at the Company's 2022 annual meeting of stockholders. The Board determined Mr. Renaud is independent under applicable SEC requirements and Nasdaq listing standards.
Compensatory Arrangements and Governance
Mr. Renaud's appointment includes the following compensatory arrangements:
- Annual Retainer: $85,000, starting on the Effective Date, pro-rated for any partial period of service.
- Stock Options: An option to purchase 71,500 shares of Common Stock granted on the Effective Date.
- Vesting Schedule: Options vest in three equal tranches (1/3rd) on the first, second, and third anniversaries of the grant date, subject to continuous service.
- Committee Assignments: Mr. Renaud has not been appointed to any Board committees and is not currently expected to be named to one.
The Company also entered into its standard form of indemnification agreement with Mr. Renaud.
Investor Verification Checklist
- Verify the independence status of Mr. Ron Renaud against the Company's Corporate Governance Guidelines.
- Review the 2020 Proxy Statement (filed April 22, 2020) for full details on the non-employee director compensation plan.
- Confirm the vesting terms and exercise price of the 71,500 stock options granted to Mr. Renaud.
- Monitor future filings for any committee assignments or changes to Mr. Renaud's role as Chair.